Hamilton, Kirk L., and Matt Kiessling. DCEBIO In the presence of maximum forskolin (10 M), the DCEBIO response was reduced and biphasic, reaching a peak response of the change in I sc of 43 Ϯ 5 A/cm 2 and then falling to a steady-state response of 17 Ϯ 10 A/cm 2 compared with DCEBIO control tissues (61 Ϯ 6 A/cm 2 ). The forskolin-stimulated Isc in the presence of DCEBIO was reduced compared with forskolin control tissues. Similar results were observed with DCEBIO and 8-BrcAMP where adenylate cyclase was bypassed. H89, a PKA inhibitor, reduced the DCEBIO-activated I sc, providing evidence that DCEBIO increased Cl Ϫ secretion via a cAMP/PKA-dependent manner. These data suggest that DCEBIO stimulates Cl Ϫ secretion of the mouse jejunum and that DCEBIO targets components of the Cl Ϫ secretory mechanism.
1-ethyl-2-benzimidazolinone; forskolin; glibenclamide; clotrimazole; H89 THE JEJUNUM is the primary site of fluid secretion of the small intestine (7) . In the mouse jejunum, as in other Cl Ϫ -secreting tissues, electrogenic Cl Ϫ secretion is the predominant transport mechanism responsible for fluid secretion and occurs within the crypt (71) , whereas absorption is a property of the villi. Cl Ϫ secretion occurs through the interplay of four membrane transporter proteins (Cl Ϫ channel, Na
, and the Na ϩ -K ϩ -ATPase). Cl Ϫ enters the cell via the bumetanide-sensitive Na ϩ -K ϩ -2Cl Ϫ cotransporter. A sustained Cl Ϫ secretory response requires active Cl Ϫ channels, as well as activated basolateral K ϩ channels, which play a crucial role in hyperpolarizing the membrane potential of the cell, thus maintaining a driving force for Cl Ϫ exit across the apical membrane via Cl Ϫ channels (68) . K ϩ channels also aid in recycling K ϩ across the basolateral membrane (68) . The Na ϩ -K ϩ -ATPase maintains the Na ϩ and K ϩ concentration gradients across the membrane. Thus Cl Ϫ secretion results in Cl Ϫ movement across the epithelium; Na ϩ and water follow via the paracellular pathway, resulting in a hydrated mucosal surface of the epithelium. Variations in the activity of any of these transport proteins can alter the rate of Cl Ϫ secretion, and thus fluid secretion, which plays a vital role in several diseases, such as cystic fibrosis (CF) (50, 70) , distal intestinal obstruction syndrome (DIOS) (17, 51) , chronic obstruction pulmonary disease (42, 49) , and diarrhea (19) .
In particular, CF affects various epithelia of the body by reducing Cl Ϫ secretion. The CF gene codes for the CF transmembrane conductance regulator (CFTR), which functions as a cAMP-dependent Cl Ϫ channel (53, 54) . Mutations in the CF gene lead to defects in CFTR, resulting in reduced Cl Ϫ and fluid secretion manifested as dehydration of the respiratory and intestinal epithelia. Intestinal complications of CF include meconium ileus (impacted ileum), malnutrition, and DIOS. Indeed, 10 -15% of infants with CF suffer from meconium ileus (48) and have a higher risk of malnutrition (37) or DIOS (51) in later life. In addition, children with CF have severely reduced Cl Ϫ transport, as determined by jejunal biopsies (45, 64) . Pharmacological modulation of ion transport has been suggested as a possible therapeutic treatment of intestinal complications of CF (36, 55) .
The benzimidazolones are a class of compounds that were first characterized as modulators of K ϩ channels. Indeed, Olesen and colleagues (46, 47) first described the effects of 5-trifluoromethyl-1-(5-chloro-2-hydroxyphenyl)-1,3-dihydro-2H-benzimidazol-2-one (NS004) and 1-(2Ј-hydroxy-5Ј-trifluoromethylphenyl)-5-trifluoromethyl-1,3-dihydro-2H-benzimidazol-2-one (NS1619) as activators of large-conductance K ϩ channels of bovine smooth muscle cells and mouse cerebellar granule cells. However, Gribkoff et al. (24) demonstrated that NS004 activated both wild-type CFTR and ⌬F508-CFTR expressed in Xenopus oocytes. Al-Nakkash et al. (1) likewise reported that NS004 activated phosphorylated ⌬F508-CFTR expressed in NIH3T3 mouse fibroblast cells. In addition, Becq and colleagues (12) have reported that NS004 activates phosphorylated (via forskolin) wild-type CFTR and G551D-CFTR expressed in Chinese hamster ovary cells. Recently, a benzimidazolone has been implicated in the modulation of the Na
Ϫ cotransporter (63) . Therefore, benzimidazolones can modulate several transport proteins involved in the Cl Ϫ secretory response.
1-Ethyl-2-benzimidazolinone (1-EBIO), another benzimidazolone, has been demonstrated to stimulate Cl Ϫ secretion in several epithelia, including the T84 colonic cell line (14) , mouse jejunum (28) and colon (11, 38) , rat colon (14, 69) , and Calu-3 human airway cells (16) , for example. 1-EBIO is a known activator of K ϩ channels (34) , in particular the intermediate-conductance Ca 2ϩ -dependent K ϩ channel (IK Ca , KCNN4) (14, 28, 33, 69) . 1-EBIO has been reported to stimulate intracellular levels of cAMP in native tissue (11, 39) ; however, others do not concur (67) . 1-EBIO increases the activity of CFTR in cultured cells (13, 16) and native epithelia (10, 38) .
Recently, 5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one (DCEBIO), a derivative of 1-EBIO, has been demonstrated to be an extremely potent activator of Cl Ϫ secretion in T84 colonic cells (61) . However, the effects of DCEBIO are yet to be determined in native epithelia. The aims of this study were twofold: first, to examine the effect of DCEBIO on the short-circuit current (I sc ) response of a native epithelium, the mouse jejunum; and second, to determine the mechanism of action of DCEBIO on the Cl Ϫ secretory response of the mouse jejunum.
MATERIALS AND METHODS

Animals and tissue preparation.
All experiments were performed on the jejunum of male Swiss-Webster mice (20 -35 g ) and were approved by the University of Otago Animal Ethics Committee. The animals had access to tap water and food ad libitum until the time of the experiment. The mice were euthanized by cervical dislocation, and the intact isolated jejunum was placed in a NaCl Ringer solution composed of (in mM) 140 NaCl, 5 KCl, 2 CaCl 2, 1 MgCl2, 10 HEPES/Tris, and 4 pyruvate/glutamine, with pH adjusted to 7.4. HEPES-buffered Ringer solution was used in these experiments to examine only HCO 3 Ϫ -independent Cl Ϫ secretion.
Electrophysiological measurements-Ussing chamber experiments.
The Ussing chamber short-circuit current experiments were performed as previously described (3, 5, 28) . Once the tissues were isolated and pinned, the tissues were glued (Loctite 454; Henkel Loctite Adhesives, Welwyn Garden City, UK) to plastic annuli (0.7 cm 2 ) and mounted in modified Ussing chambers. In all experiments, tissues were bathed on both mucosal and serosal sides with 10 ml of the NaCl Ringer solution. Solutions were aerated (100% O 2) and maintained at 37°C by water-jacketed solution reservoirs.
Tissues were voltage clamped to 0 mV (Biodesign, South Campus Electronics, University of Otago), and I sc was continuously recorded with a MacLab data-acquisition system (ADInstruments, Castle Hill, Australia) (3, 5, 28) . Initially, tissues were rinsed three times with NaCl Ringer solution. After that, all tissues were pretreated with indomethacin (1 M, mucosal and serosal) to reduce prostaglandin production (20) and tetrodotoxin (0.6 M, serosal) to reduce enteric nerve activity (31) for 1 h (total time) to reduce transepithelial transport to basal conditions. Data analysis was performed with MacLab Chart (version 3.6.3; ADInstruments). The basal I sc was 87 Ϯ 3 A/cm 2 (n ϭ 175 tissues, N ϭ 75 animals). The change in Isc (⌬Isc) induced by a treatment was expressed as the difference from the former baseline to the steady state. In the case of a biphasic response, two ⌬I sc values were measured: 1) from the former baseline to the peak response and 2) from the former baseline to the steady-state response. Concentration-dependent response curves were fit with the Hill equation. The presence of the circular and longitudinal muscle layers surrounding the jejunum did not impede access of chemicals to the epithelium, as exhibited by very rapid responses of I sc with the addition of forskolin or bumetanide (see Figs. 1, 2, 4 -6) .
Chemicals. Dr. Robert J. Bridges (University of Pittsburgh) graciously provided the DCEBIO for this study. HEPES, indomethacin, forskolin, bumetanide, glibenclamide, 8-bromoadenosine 3Ј,5Ј-cyclic monophosphate (8-BrcAMP), 5-nitro-2-(3-phenylpropylamino)-benzoate (NPPB), H89, and clotrimazole were purchased from Sigma (St. Louis, MO). In some figures, the SE bar is within the symbol. A P value of Յ0.05 was considered significant. The number of tissues for a given protocol and the number of animals used in a series of experiments are provided in the text. Sometimes more than one tissue from an animal was used for a particular protocol within a given series of experiments.
RESULTS
DCEBIO-activated Cl
Ϫ secretion of the mouse jejunum. Initially, we determined whether DCEBIO could activate an I sc response of the mouse jejunum. DCEBIO (100 M, serosal) stimulated a sustained increase in I sc (⌬I sc of 74 Ϯ 8 A/cm 2 , n ϭ 8, N ϭ 6) (Fig. 1, A and D) compared with control tissues (⌬I sc of Ϫ5 Ϯ 10 A/cm 2 , n ϭ 5) (Fig. 1, C and D) . DCEBIO was also effective when added from the mucosal side of the tissue. Mucosal addition of DCEBIO (100 M) (Fig. 1B) activated I sc by 41 Ϯ 1 A/cm 2 (n ϭ 3, N ϭ 3) (Fig. 1E ), which was greater (P Ͻ 0.01) than paired control tissues (Ϫ5 Ϯ 5 A/cm 2 , n ϭ 3). DCEBIO (1-125 M, serosal) stimulated a concentrationdependent increase in I sc as shown in Fig. 2A . This relationship exhibited a V max of 102 Ϯ 2 A/cm 2 , an EC 50 of 41 Ϯ 1 M, and Hill coefficient of 1.9 Ϯ 0.1 (Fig. 2 , A and C, circles) (n ϭ 6 -8 per data point, N ϭ 4). However, 1-EBIO, the parent molecule of DCEBIO (61), was less potent than DCEBIO. 1-EBIO, too, increased I sc in a concentration-dependent manner with a V max of 86 Ϯ 8 A/cm 2 , an EC 50 of 862 Ϯ 150 M and Hill coefficient of 1.6 Ϯ 0.3 (n ϭ 8 -11 per data point, N ϭ 7, data not shown) as has been demonstrated by us and others (14, 28) .
We used bumetanide, a known blocker of the basolateral Na
Ϫ cotransporter the entry step for Cl Ϫ in the Cl (Fig. 1, B and E) . (19, 52) and is present in the mouse jejunum (2) . Therefore, we tested for the participation of CFTR in the DCEBIO-stimulated I sc response with glibenclamide and NPPB, known blockers of CFTR (10, 58, 60, 73) . We (3) recently demonstrated that mucosally applied glibenclamide reduced the forskolin-activated I sc of the mouse jejunum by 60%. Similarly, we (27) reported that mucosal rather than serosal applied glibenclamide reduced methoxsalen-stimulated Cl Ϫ secretion of the mouse jejunum, suggesting that glibenclamide does not have access to the opposite side of the epithelium. Seven animals were used in this series of experiments. For each animal, two tissues were pretreated (30 min) with glibenclamide (100 M, mucosal), whereas a third tissue was treated with DMSO only. After that, DCEBIO (100 M, serosal) was added to one of the glibenclamide-treated tissues and to the DMSO tissue. In control tissues, DCEBIO activated I sc by 63 Ϯ 11 A/cm 2 ( Fig. 3 , A and D) (n ϭ 6); however, DCEBIO increased I sc by only 12 Ϯ 8 A/cm 2 in the presence of glibenclamide (Fig. 3 , B and D) (n ϭ 7) in paired experimental tissues. Therefore, pretreatment of tissues with glibenclamide reduced the action of DCEBIO by 81%. In addition, glibenclamide (100 M, mucosal) added in the presence of DCEBIO (100 M, serosal) reduced the DCEBIOstimulated I sc by 77 Ϯ 10% compared with paired DCEBIO control tissues (n ϭ 5, N ϭ 5, data not shown).
In similar experiments, pretreatment of tissues with NPPB (50 or 100 M, mucosal), another inhibitor of CFTR (10, 73) , greatly reduced DCEBIO-stimulated I sc compared with DCEBIO control tissues (n ϭ 4, N ϭ 4, data not shown).
These results demonstrate that CFTR participates in the DCEBIO-stimulatory Cl Ϫ secretory response of the mouse jejunum.
One of the predominant K ϩ channels present in the basolateral membrane of mouse crypt cells appears to be KCNN4, the IK Ca channel (6, 28) . As far as we are aware, the molecular identity of IK Ca in the mouse jejunum has yet to be reported (D. Vandorpe, unpublished observation). However, IK Ca has been demonstrated in mouse stomach, proximal colon, and distal colon (66) . We (6, 28) have functionally (patch clamp) demonstrated that 1-EBIO activates IK Ca in the mouse jejunum, and others (11, 14) have reported similar findings in native epithelia and cultured cells. On the basis of excised patch experiments, Bridges and co-workers (61) demonstrated that DCEBIO directly activates IK Ca expressed in human embryonic kidney (HEK)-293 cells. We (62) have confirmed those findings. So, it was of great interest to determine whether IK Ca participated in the DCEBIO-stimulated I sc . Clotrimazole has been demonstrated to inhibit IK Ca in both heterologous systems and native epithelia (15, 56, 57, 72) . Therefore, the effect of clotrimazole (3 M, serosal) on the action of DCEBIO (100 M, serosal) was assessed with seven animals.
Experimental tissues were pretreated (30 min) with clotrimazole, whereas control tissues were pretreated with DMSO. Pretreatment with clotrimazole significantly reduced the activation of I sc by DCEBIO (⌬I sc of 13 Ϯ 9 A/cm 2 , n ϭ 6) ( 4, B and D) compared with paired DCEBIO control tissues (⌬I sc of 55 Ϯ 6 A/cm 2 , n ϭ 8) (Fig. 4, A and D) . Clotrimazole reduced the DCEBIO-stimulated I sc by 67 Ϯ 15%. These data suggest that the Ca 2ϩ -activated K ϩ channel participates in the DCEBIO-activated I sc response.
Do DCEBIO and forskolin share a common pathway in activating Cl
Ϫ secretion? Cuthbert and colleagues (11, 39) have demonstrated that 1-EBIO (Ն600 M) elevates intracellular cAMP levels of isolated mouse colonic crypts. However, Wallace et al. (67) did not demonstrate an effect of 1-EBIO (600 M) on intracellular cAMP levels of T84 colonic cells. We have demonstrated that DCEBIO-stimulated Cl Ϫ secretion is reduced by glibenclamide (Fig. 3) and NPPB, indicative of the participation of CFTR. Bridges and colleagues (61) reported that DCEBIO (60 M) activates Cl Ϫ currents (via CFTR) in basolaterally nystatin permeablized T84 monolayers, which suggests that CFTR is activated by DCEBIO. Because CFTR participated in the DCEBIO response in the present study, then in the presence of a maximal concentration of forskolin, an activator of CFTR via adenylyl cyclase, and thus cAMP/PKA, we predict that the DCEBIO-stimulated I sc should be reduced. We used six animals to test this hypothesis. Tissues were either pretreated with maximal forskolin (10 M, mucosal and serosal; unpublished data), followed by the addition of DCEBIO (100 M, serosal) or treated with DMSO before DCEBIO. As noted above, DCEBIO stimulated a sustained increase in I sc (61 Ϯ 6 A/cm 2 , n ϭ 6) in the absence of forskolin as shown in Fig. 5 , B and D. Pretreatment of tissues with forskolin increased I sc by 82 Ϯ 13 A/cm 2 ( Fig. 5C ) (n ϭ 6). However, in the presence of a maximal forskolin-stimulated I sc response, the DCEBIO-activated I sc response was biphasic and reduced, reaching a peak response of ⌬I sc of 43 Ϯ 5 A/cm 2 and then falling to a sustained response of 17 Ϯ 10 A/cm 2 above the I sc stimulated by forskolin (Fig. 5 , C and D) (n ϭ 6). These experiments are summarized in Fig. 5D . These data suggest that DCEBIO and forskolin may share a common pathway (CFTR).
On the basis of these data, if CFTR participates in the DCEBIO-activated I sc response, then we predict that pretreating tissues with a maximum concentration of DCEBIO should reduce the forskolin-stimulated I sc response of the mouse jejunum. Five animals were used to test this hypothesis. Tissues were subjected to DCEBIO (100 M, serosal) followed by forskolin (10 M, mucosal and serosal) or to DMSO followed by forskolin. Pretreatment of tissues with DCEBIO increased the I sc by 35 Ϯ 8 A/cm 2 (n ϭ 5) (Fig. 6C ). However, in the presence of DCEBIO, the forskolin-stimulated I sc was significantly reduced by 63% (⌬I sc of 31 Ϯ 7 A/cm 2 , n ϭ 5) (Fig. 6 , B and C) compared (P Ͻ 0.01) with paired forskolin control tissues (⌬I sc by 84 Ϯ 11 A/cm 2 , n ϭ 5) (Fig.  6, A and C) . DCEBIO stimulated I sc by 45 Ϯ 9 A/cm 2 (n ϭ 5) in control tissues.
Again, these results demonstrate that DCEBIO and forskolin increase the I sc of the mouse jejunum via a similar pathway and provide further evidence that CFTR participates in the DCE-BIO-stimulated increase in I sc .
It was surprising that DCEBIO and forskolin did not have an additive effect on the stimulated I sc of the mouse jejunum. However, forskolin (10 M) has been shown to increase intracellular Ca 2ϩ levels in epithelial tissues such as mouse tracheal and nasal epithelia (26, 38) . However, Greger and (15) reported that a higher concentration of clotrimazole was required for cAMP-dependent compared with Ca 2ϩ -dependent agonists of Cl Ϫ secretion. Five animals were used in this series of experiments. Two tissues were pretreated with clotrimazole (for 30 min), followed by the addition of forskolin (10 M, mucosal and serosal), whereas a control tissue was pretreated with DMSO followed by forskolin. As shown in Fig.  7 , even in the presence of 20 M clotrimazole, forskolin still activated I sc by 48 Ϯ 5 A/cm 2 (n ϭ 5) (Fig. 7, B and C) , which was reduced compared (P Ͻ 0.01) with forskolin control tissues (⌬I sc of 83 Ϯ 9 A/cm 2 , n ϭ 10) (Fig. 7, A and C) . Clotrimazole reduced the forskolin-activated I sc by 48 Ϯ 5%. These data suggest that IK Ca is modulated by forskolin in the forskolin-stimulated I sc response.
Does DCEBIO stimulate Cl Ϫ secretion via a cAMP-dependent mechanism? The data presented suggest that DCEBIO and forskolin use a similar pathway(s) to stimulate Cl Ϫ secretion. Therefore, if DCEBIO, in fact, is working via cAMP (PKA) to activate CFTR and also stimulating IK Ca , resulting in a sustained I sc response, then if we prephosphorylated CFTR with a very low concentration of forskolin (0.25 M), we predict that the DCEBIO concentration-dependent increase of I sc would be reduced (V max ) and the EC 50 would shift to a higher concentration of DCEBIO. To test this hypothesis, we used six animals. As shown in Fig. 2B , pretreament of tissues with 0.25 M (mucosal and serosal) forskolin increased ⌬I sc by 18 Ϯ 7 A/cm 2 (n ϭ 6), after which DCEBIO (1-125 M, serosal) increased I sc in a concentration-dependent manner (n ϭ 6 per data point) (Fig. 2, B and C, filled triangles) . However, as predicted, the EC 50 for the DCEBIO concentration-dependent response in the presence of 0.25 M forskolin, was shifted from 41 Ϯ 1 M (Fig. 2C, filled circles) (DCEBIO alone) to 53 Ϯ 5 M (Fig. 2C , filled triangles, DCEBIO with forskolin), whereas V max was reduced from 102 Ϯ 2 A/cm 2 ( Fig. 2C , filled circles) to 58 Ϯ 4 A/cm 2 ( Fig. 2C , filled triangles) (n ϭ 6, N ϭ 6) (Fig. 2C) .
These data suggest that prephosphorylating CFTR with a submaximal concentration of forskolin reduces the effect of DCEBIO on I sc . Again, one could interpret these data to suggest that forskolin, via increasing intracellular Ca 2ϩ , has increased the activity of IK Ca before the addition of DCEBIO, thus reducing the potential action of DCEBIO. However, we believe this is not the case for the DCEBIO concentrationdependent experiments that were conducted with a very low concentration of forskolin. Nonetheless, to further examine the hypothesis that the action of DCEBIO involved cAMP, as well as activating I sc via IK Ca , we examined the effects of DCEBIO on I sc in the presence and absence of 8-BrcAMP, thus passing the level of adenylyl cyclase. 8-BrcAMP (1-300 M, mucosal and serosal) stimulated a concentration-dependent increase in I sc with a V max of 78 Ϯ 2 A/cm 2 and a EC 50 of 58 Ϯ 2 M (n ϭ 4 -7 per data point, N ϭ 4, data not shown). The experimental protocols were similar to those used in the DCEBIO and forskolin experiments described above (Figs. 5  and 6 ). On the basis of the forskolin-DCEBIO experiments (see Fig. 5 ), we predicted that pretreatment of tissues with a maximum concentration of 8-BrcAMP (300 M, mucosal and serosal) would reduce the peak and steady-state I sc response of DCEBIO. In this series of experiments, three animals were used to test this hypothesis. One tissue was pretreated with 8-BrcAMP for 30 min, followed by the addition of DCEBIO (100 M, serosal), whereas a paired tissue was treated with DMSO before DCEBIO. DCEBIO stimulated a sustained increase in I sc (55 Ϯ 17 A/cm 2 ; n ϭ 3) in the absence of 8-BrcAMP as shown in Fig. 8 , A and C. However, in the presence of a maximal 8-BrcAMP-stimulated I sc response (⌬I sc of 74 Ϯ 3 A/cm 2 , n ϭ 3), the DCEBIO response was once again biphasic with a peak response of ⌬I sc of 44 Ϯ 2 A/cm 2 and then falling to a sustained response of 8 Ϯ 6 A/cm 2 above the I sc stimulated by 8-BrcAMP (Figs. 8, B and C) (n ϭ 3) .
Working from these data, if DCEBIO increased intracellular cAMP, then we predicted that pretreating tissues with a maximum concentration of DCEBIO (100 M, serosal) would reduce the 8-BrcAMP-stimulated I sc response. We used four animals to test this hypothesis. These experiments were conducted with similar protocols as described for the DCEBIOforskolin experiments (see Fig. 6 ). Tissues were subjected to DCEBIO, followed by 8-BrcAMP (300 M, mucosal and serosal) or DMSO, followed by 8-BrcAMP. Pretreatment of tissues with DCEBIO increased I sc by 61 Ϯ 6 A/cm 2 ( Fig.  9B) (n ϭ 4) . However, in the presence of DCEBIO, the 8-BrcAMP-stimulated I sc was significantly reduced by 76% (⌬I sc of 16 Ϯ 6 A/cm 2 , n ϭ 4) (Fig. 9 , B and C) compared (P Ͻ 0.05) with paired 8-BrcAMP control tissues (⌬I sc of 68 Ϯ 17 A/cm 2 , n ϭ 4) (Fig. 9, A and C) . Our data suggest that DCEBIO may activate I sc via a cAMP/PKA-dependent mechanism. If this were the case, then we predicted that an inhibitor of PKA would reduce the DCEBIO-activated I sc . H89 is a relatively specific inhibitor of PKA (29) and has been used (10 -50 M) to demonstrate the PKA dependence of several transport proteins of native tissues (18, 41, 65) . Therefore, we used H89 (50 M, serosal) to test the hypothesis that DCEBIO activates I sc via a cAMP/PKAdependent manner. Five animals were used in this series of experiments. In addition, with paired tissues from the same animals, we also examined the effect of H89 on forskolinstimulated I sc . Tissues were pretreated with either H89 (50 M, serosal) or H 2 O for 30 min before the addition of either DCEBIO (100 M, serosal) or forskolin (10 M, mucosal and serosal). H89 did not alter the basal I sc (Fig. 10) . Indeed, H89 reduced the DCEBIO-activated I sc (⌬I sc of 37 Ϯ 3 A/cm 2 , n ϭ 5) (Fig. 10, B and C) compared with (P Ͻ 0.01) paired (Fig.  10, A and C) . In a similar fashion, the presence of H89 reduced the forskolin-stimulated I sc (⌬I sc of 36 Ϯ 10 A/cm 2 , n ϭ 5) (Fig. 10 , E and F) compared (P Ͻ 0.01) with paired forskolin control tissues (⌬I sc of 102 Ϯ 16 A/cm 2 , n ϭ 5) (Fig. 10, D  and F) .
These data strongly suggest that DCEBIO activates I sc (Cl Ϫ secretion) via a cAMP/PKA-dependent mechanism, as well as the participation of IK Ca .
DISCUSSION
In this report, we provide the first examination of the effects of the benzimidazolone DCEBIO on the Cl Ϫ secretory response of any native epithelium, the mouse jejunum. In addition to the involvement of IK Ca , we have demonstrated for the first time that the mechanism of action of DCEBIO includes the cAMP/PKA pathway. DCEBIO stimulated a concentrationdependent, sustained increase in I sc of the mouse jejunum ( Figs. 1 and 2) . We (27, 28) and others (8, 9, 25) have demonstrated electrogenic Cl Ϫ secretion of the mouse jejunum. Therefore, we used bumetanide to confirm that DCEBIO stimulated I sc consistent with Cl Ϫ secretion. Indeed, bumetanide reduced the DCEBIO-activated I sc by Ͼ80% (Fig. 1) , without regard to which side of the tissue DCEBIO was added. In the present study, the IC 50 for bumetanide inhibition for DCEBIOactivated Cl Ϫ secretion was 0.9 M, which is very similar to bumetanide inhibition of I sc of the flounder intestine (0.7 M) (43, 44), T84 cells (2 M) (22), and mouse jejunum (0.7 M) (27), for example.
The bumetanide-insensitive, DCEBIO-stimulated I sc may well be HCO 3 Ϫ secretion (25, 59) ; however, the present experiments were conducted in HEPES-buffered Ringer solution. Thus, if HCO 3 Ϫ secretion occurred, the CO 2 source could have been from metabolically generated CO 2 .
DCEBIO: modulation of components of Cl Ϫ secretion. The sustained Cl Ϫ secretory response exhibited by DCEBIO suggests that multiple transport proteins of the Cl Ϫ secretory pathway are involved in the DCEBIO response. Indeed, Bridges and colleagues (61) reported that DCEBIO activated CFTR in nystatin-permeablized basolateral membranes of T84 monolayers, similarly to NS004 (13) . They also reported that DCEBIO stimulated the activity of IK Ca expressed in HEK-293 cells (61), which we have confirmed (62) .
Several lines of evidence suggest that CFTR and IK Ca participate in the DCEBIO response of the mouse jejunum. First, CFTR is expressed in the mouse intestine and in the jejunum in particular (2) . Second, a maximum phosphorylation of CFTR via adenylyl cyclase (with forskolin) greatly reduced the action of DCEBIO (Fig. 5) . In fact, DCEBIO in the presence of forskolin resulted in a biphasic increase of I sc , which had a reduced peak response compared with DCEBIO alone, and a steady-state I sc that remained above the increased I sc level activated by forskolin. The hypothesis for this experiment was twofold: 1) if DCEBIO alters cAMP levels, as some have described for 1-EBIO (11, 39) , then maximal stimulation of I sc by DCEBIO, in the presence of forskolin, should be reduced compared with DCEBIO alone; and 2) in the presence of a maximal cAMP signal (via forskolin), DCEBIO could further increase the I sc by the stimulation of IK Ca . This appears to be the case; however, we were surprised by the fall in DCEBIO-stimulated I sc to a lower steady-state level (Fig. 5C ) in the presence of forskolin. We did not observe this response during similar experiments with 1-EBIO (unpublished data). At present, we are uncertain as to the complex transient activation of I sc stimulated by DCEBIO in the presence of forskolin. Undoubtedly, the transient activation of I sc could result from a further hyperpolarization of the membrane potential (i.e., activation of IK Ca ). However, the subsequent decline of I sc to a new lower steady state would depend on the following: 1) a reduced hyperpolarization (i.e., slight decrease in K ϩ conductance), 2) an increase in activity of CFTR or an as yet undescribed component of the Cl Ϫ conductance without activation of K ϩ conductance, or 3) possibly an altered function of the Na ϩ -K ϩ -ATPase. However, Koegel et al. (35) reported that 1-EBIO downregulated IK Ca of keratinocytes over an exposure time of hours, whereas they noted a stimulation of IK Ca over a time frame of minutes. This would not explain our current results, because we noted a reduction of DCEBIO-stimulated I sc in Ͻ5 min after the peak I sc response (Fig. 5C ). Third, pretreatment of the mouse jejunum with a maximum concentration of DCEBIO greatly reduced the effect of forskolin (Fig. 6 ), suggesting that DCEBIO and forskolin might use a common pathway for activating Cl Ϫ secretion. Fourth, mucosally applied glibenclamide, a known inhibitor of CFTR (58, 60) , reduced the DCEBIO-stimulated I sc by Ͼ80% (Fig. 3) . We (27) have previously demonstrated that glibenclamide applied from the serosal solution did not affect Cl Ϫ secretion of the mouse jejunum, suggesting that the effect of glibenclamide is on a transport protein (e.g., CFTR) that resides in the apical membrane. Finally, mucosally applied NPPB also reduced the DCEBIO-stimulated I sc .
Although IK Ca has yet to be verified in the mouse jejunum by molecular techniques, IK Ca is present within the mouse stomach and proximal and distal colon (66) . IK Ca is the predominant K ϩ channel of the basolateral membrane of the mouse jejunal crypt cell (6, 28) . Clotrimazole, a known inhibitor of IK Ca (15, 56, 57) , was used to demonstrate the participation of IK Ca in the DCEBIO-stimulated I sc response. Clotrimazole greatly reduced the secretory response (I sc ) of the mouse jejunum by DCEBIO (Fig. 4) . We have not examined the effects of DCEBIO and clotrimazole at the single-channel level of IK Ca of jejunal crypts. However, we have demonstrated, using excised patch-clamp experiments, that clotrimazole inhibits DCEBIO-stimulated IK Ca channel activity with a K i of 65 nM for IK Ca expressed in HEK-293 cells (62 (14, 28, 33, 69) and stimulates CFTR in nystatin-permeablized preparations (13, 16) . Cuthbert and colleagues (11, 39) have demonstrated that 1-EBIO (Ն600 M) increases cAMP via activation of adenylyl cyclase; however, Wallace et al. (67) , using the same concentration of 1-EBIO, did not observe an effect of 1-EBIO on cAMP in T84 cells.
In the present study, we have several lines of evidence that suggest that in addition to activating IK Ca , DCEBIO appears to increase Cl Ϫ secretion in a cAMP-dependent manner. First, pretreating tissues with 0.25 M forskolin, an activator of adenylyl cyclase, reduced and shifted the DCEBIO concentration-dependence curve (Fig. 2) with a reduction in V max and a rightward shift of EC 50 . It could be interpreted that the modest amount of forskolin used in those experiments may have increased intracellular Ca 2ϩ ; however, we think that this is not the case. Greger and colleagues (4, 23) demonstrated that forskolin (10 M) reduced Ca 2ϩ levels in isolated rat colonic crypts, whereas Cuthbert and colleagues (40) reported little effect of forskolin (10 M) on intracellular Ca 2ϩ of cultured human colonic cells (colony 29). Considering that we used a concentration of forskolin (0.25 M) that was five times lower, forskolin may not alter intracellular Ca 2ϩ but slightly raise cAMP and thus phosphorylate CFTR. Therefore, we think that in the presence of low forskolin, DCEBIO can further increase intracellular cAMP, thereby increasing the activity of CFTR while activating IK Ca , resulting in a sustained Cl Ϫ secretory response. Second, we demonstrated that pretreatment of tissues with 300 M 8-BrcAMP (a maximal concentration for activating I sc in the mouse jejunum) reduced the DCEBIO-stimulated I sc (Fig. 8) . Likewise, pretreatment of tissues with DCEBIO (100 M) reduced the 8-BrcAMP-activated I sc (Fig. 9) . It could be argued that pretreatment of 300 M 8-BrcAMP may have increased either intracellular Ca 2ϩ or activated IK Ca before the subsequent addition of DCEBIO. However, it has been reported that 1 mM 8-BrcAMP altered neither intracellular Ca 2ϩ levels nor the activity of IK Ca in Calu-3 cells (32). Holz et al. (30) reported that 1 mM 8-BrcAMP resulted in a fast transient increase in intracellular Ca 2ϩ in primary cultures of rat pancreatic ␤-cells. In the present study, we have used a low concentration (300 M) of 8-BrcAMP compared with these other studies, and therefore we suggest that DCEBIO increases cAMP, which is then augmented by the addition of 8-BrcAMP (Fig. 9) . The small increase in I sc with 8-BrcAMP in the presence of DCEBIO was not surprising, because Cuthbert et al. (11) reported that high concentrations of 1-EBIO was not as effective as forskolin in stimulating cAMP levels of the mouse colon.
Finally, if DCEBIO activates Cl Ϫ secretion via a cAMPdependent manner, as well as by activating IK Ca , then a PKA inhibitor should reduce the effect of DCEBIO on I sc . Indeed, H89 significantly reduced the DCEBIO-stimulated I sc by 34 Ϯ 6% (Fig. 10, A-C) . Similarly in paired tissues, H89 reduced the forskolin-stimulated I sc by 66 Ϯ 8% (Fig. 10, D-F) . In addition, Turner et al. (65) demonstrated that H89 (10 M) reduced forskolin-and epinephrine-stimulated I sc of rabbit conjunctival epithelium. Similarly, Erlenkamp et al. (18) reported that PKA was stimulated by forskolin and inhibited by H89 (50 M) in ventricular myocytes of the guinea pig.
Potency of DCEBIO compared with 1-EBIO. The only difference between DCEBIO and its parent molecule 1-EBIO is the presence of chloro groups at positions 5 and 6 on the phenyl ring of the benzimidazolone structure (61) . The chloro groups at those positions fulfill an optimal size and electronic character not achieved by bromo or methyl groups (61) . Indeed, this slight change in the structure of the benzimidazolone significantly enhances the potency of DCEBIO over 1-EBIO. Bridges and colleagues (61) reported that DCEBIO exhibited an EC 50 of 45 M, whereas 1-EBIO had an EC 50 of 1,200 M in I sc experiments of T84 colonic monolayers. Similarly, with a native epithelium, the mouse jejunum, we report herein the EC 50 of DCEBIO and 1-EBIO on I sc were 41 M and 862 M, respectively (Fig. 2) . We and others have reported that 1-EBIO exhibits an EC 50 on I sc for Cl Ϫ secretion of between 0.5 and 1 mM for Cl Ϫ secretion in cultured cells and native epithelia (11, 14, 16, 28, 61) . Similarly, with patch-clamp experiments, the EC 50 of DCEBIO on the activation of IK Ca channels expressed in Xenopus oocytes is 840 nM (61) and 4 M for IK Ca expressed in HEK-293 cells (62) , However, the EC 50 for activation of IK Ca by 1-EBIO for native IK Ca channels of T84 colonic cells (61) and IK Ca expressed in HEK-293 cells (33) is ϳ80 M. The lower EC 50 in patch-clamp experiments of IK Ca is not surprising, considering the accessibility of the drug to the channel. Without a doubt, DCEBIO is a more potent activator of Cl Ϫ secretion and IK Ca than 1-EBIO. In summary, we have used the Ussing chamber short-circuit current technique to demonstrate for the first time in a native epithelium that DCEBIO stimulates a Cl Ϫ secretory response of the mouse jejunum. Both CFTR and IK Ca participate in the DCEBIO-activated Cl Ϫ secretory response. The action of DCEBIO, as well as activation of IK Ca , appears to occur in a cAMP-dependent manner.
NOTE ADDED IN PROOF After our manuscript was accepted, we became aware of the recent article by Ayabe et al. (2a) . On the basis of RT-PCR results, they reported the presence of mRNA of mIK1 in the lower portion of the crypt of the mouse small intestine. The specific region of the small intestine was not noted. In addition, Ayabe et al. detected mRNA of mIK1 only in the paneth cells of the crypt; however, they stated that other cell types of the crypt may express mIK1 at levels below the detection limits of their assay.
